Objectif
Smoking is the largest avoidable cause of preventable morbidity worldwide. It causes most of the cases of lung cancer and chronic obstructive pulmonary disease (COPD) and contributes to the development of other lung diseases. The control of smoking is considered as a highly important intervention for the prevention of lung diseases. Tobacco consumption is highly influenced by socioeconomic factors. SmokeFreeBrain aims to address the effectiveness of a multi-level variety of interventions aiming at smoking cessation in high risk target groups within High Middle Income Countries (HMIC) such as unemployed young adults, COPD and asthma patients, as well as within the general population in Low Middle Income Countries (LMIC). The project addresses existing approaches aiming to prevent lung diseases caused by tobacco while at the same time it develops new treatments and analyzes their contextual adaptability to the local and global health care system.
SmokeFreeBrain follows an interdisciplinary approach exploiting consortium’s expertise in various relevant fields in order to generate new knowledge. State of the art techniques in toxicology, pulmonary medicine, neuroscience and behavior will be utilized to evaluate the effectiveness of: (i) Public Service Announcement (PSA) against smoking, (ii) the use of electronic cigarettes with and without nicotine as a harm reduction approach and/or cessation aid, (iii) a specifically developed neurofeedback intervention protocol against smoking addiction, (iv) a specifically developed intervention protocol based on behavioral therapy, social media/mobile apps and short text messages (sms) and (v) pharmacologic interventions. The main objective of the project is to evaluate the interventions in terms of health economics, by studying their cost-effectiveness, and proposing a scalable plan and a clear pathway to embedding the proposed interventions into policy and practice both in LMIC as well as in HMIC.
Champ scientifique
- medical and health sciencesclinical medicinepneumologyasthma
- medical and health sciencesclinical medicineoncologylung cancer
- medical and health sciencesbasic medicinephysiology
- engineering and technologyelectrical engineering, electronic engineering, information engineeringinformation engineeringtelecommunicationsradio technology
- medical and health sciencesbasic medicinetoxicology
Programme(s)
Thème(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
546 36 THESSALONIKI
Grèce
Voir sur la carte
Participants (14)
Participation terminée
GU2 7XH Guildford
Voir sur la carte
LS2 7UE Leeds
Voir sur la carte
1065 Lefkosia
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
00185 Roma
Voir sur la carte
41071 Sevilla
Voir sur la carte
4400 PAZARDJIK
Voir sur la carte
55 535 THESSALONIKI
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
Participation terminée
26335 Patras
Voir sur la carte
41927 Mairena Del Aljarafe
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
21204 Sremska Kamenica
Voir sur la carte
41004 Sevilla
Voir sur la carte
SW17 0RE London
Voir sur la carte
185 33 PIRAEUS
Voir sur la carte
11031 Taipei
Voir sur la carte